Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
Emergent BioSolutions operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Emergent BioSolutions's operating cash flow for the twelve months ending Sep 30, 2026 was $200.10M, up 1439.2% year over year. For fiscal 2025 it was $170.60M, up 190.6% from the year before. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $536.90M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.60M | +190.6% |
| FY2024 | Dec 31, 2024 | $58.70M | – |
| FY2023 | Dec 31, 2023 | -$206.30M | – |
| FY2022 | Dec 31, 2022 | -$34.10M | -110.6% |
| FY2021 | Dec 31, 2021 | $320.20M | -40.4% |
| FY2020 | Dec 31, 2020 | $536.90M | +185.6% |
| FY2019 | Dec 31, 2019 | $188.00M | +349.8% |
| FY2018 | Dec 31, 2018 | $41.80M | -79.9% |
| FY2017 | Dec 31, 2017 | $208.10M | +281.1% |
| FY2016 | Dec 31, 2016 | $54.60M | +28.4% |
| FY2015 | Dec 31, 2015 | $42.52M | -62.1% |
| FY2014 | Dec 31, 2014 | $112.32M | +15.8% |
| FY2013 | Dec 31, 2013 | $96.97M | +144.6% |
| FY2012 | Dec 31, 2012 | $39.64M | +225.3% |
| FY2011 | Dec 31, 2011 | $12.19M | -87.6% |
| FY2010 | Dec 31, 2010 | $98.02M | +228.2% |
| FY2009 | Dec 31, 2009 | $29.87M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $100.10M | – |
| Q2 FY2026 | Jun 30, 2026 | $56.10M | -47.3% |
| Q1 FY2026 | Mar 31, 2026 | -$33.80M | – |
| Q4 FY2025 | Dec 31, 2025 | $77.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.30M | -101.5% |
| Q2 FY2025 | Jun 30, 2025 | $106.40M | +124.0% |
| Q1 FY2025 | Mar 31, 2025 | -$11.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$79.90M | -348.9% |
| Q3 FY2024 | Sep 30, 2024 | $153.70M | +156.2% |
| Q2 FY2024 | Jun 30, 2024 | $47.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$62.60M | – |
| Q4 FY2023 | Dec 31, 2023 | $32.10M | -65.4% |
| Q3 FY2023 | Sep 30, 2023 | $60.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$114.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$184.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $92.80M | -71.7% |
| Q3 FY2022 | Sep 30, 2022 | -$74.00M | -543.1% |
| Q2 FY2022 | Jun 30, 2022 | -$15.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.30M | -831.4% |
| Q4 FY2021 | Dec 31, 2021 | $328.10M | +33.4% |
| Q3 FY2021 | Sep 30, 2021 | $16.70M | -84.1% |
| Q2 FY2021 | Jun 30, 2021 | -$29.70M | -123.2% |
| Q1 FY2021 | Mar 31, 2021 | $5.10M | -91.2% |
| Q4 FY2020 | Dec 31, 2020 | $246.00M | +101.5% |
| Q3 FY2020 | Sep 30, 2020 | $105.20M | – |
| Q2 FY2020 | Jun 30, 2020 | $127.90M | – |
| Q1 FY2020 | Mar 31, 2020 | $57.80M | -44.8% |
| Q4 FY2019 | Dec 31, 2019 | $122.10M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.10M | -101.8% |
| Q2 FY2019 | Jun 30, 2019 | -$35.80M | -203.5% |
| Q1 FY2019 | Mar 31, 2019 | $104.80M | – |
| Q4 FY2018 | Dec 31, 2018 | -$165.80M | -314.0% |
| Q3 FY2018 | Sep 30, 2018 | $174.00M | +398.0% |
| Q2 FY2018 | Jun 30, 2018 | $34.60M | -35.9% |
| Q1 FY2018 | Mar 31, 2018 | -$1.00M | -102.4% |
| Q4 FY2017 | Dec 31, 2017 | $77.49M | – |
| Q3 FY2017 | Sep 30, 2017 | $34.94M | – |
| Q2 FY2017 | Jun 30, 2017 | $54.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $41.67M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.65M | – |
See a number that looks wrong?